Fetal and Neonatal Illnesses Caused or Influenced by Maternal Transplacental IgG and/or Therapeutic Antibodies Applied During Pregnancy

  • György BerencsiIII
  • Katalin N. Szomor


The human fetus is protected by the mother’s antibodies. At the end of the pregnancy, the concentration of maternal antibodies is higher in the cord blood, than in the maternal circulation. Simultaneously, the immune system of the fetus begins to work and from the second trimester, fetal IgM is produced by the fetal immune system specific to microorganisms and antigens passing the maternal-fetal barrier. The same time the fetal immune system has to cope and develop tolerance and TREG cells to the maternal microchimeric cells, latent virus-carrier maternal cells and microorganisms transported through the maternal-fetal barrier.

The maternal phenotypic inheritance may hide risks for the newborn, too. Antibody mediated enhancement results in dengue shock syndrome in the first 8 month of age of the baby.

A series of pathologic maternal antibodies may elicit neonatal illnesses upon birth usually recovering during the first months of the life of the offspring. Certain antibodies, however, may impair the fetal or neonatal tissues or organs resulting prolonged recovery or initiating prolonged pathological processes of the children.

The importance of maternal anti-idiotypic antibodies are believed to prime the fetal immune system with epitopes of etiologic agents infected the mother during her whole life before pregnancy and delivery.

The chemotherapeutical and biological substances used for the therapy of the mother will be transcytosed into the fetal body during the last two trimesters of pregnancy. The long series of the therapeutic monoclonal antibodies and conjugates has not been tested systematically yet. The available data are summarised in this chapter.

The innate immunity plays an important role in fetal defence. The concentration of interferon is relative high in the placenta. This is probably one reason, why the therapeutic interferon treatment of the mother does not impair the fetal development.


Respiratory Syncytial Virus Juvenile Idiopathic Arthritis TREG Cell Kawasaki Disease Progressive Multifocal Leukoencephalopathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abrams ML, Smidt A, Benjamin L, Chen M, Woodley D, Mancini AJ (2011) Congenital epidermolysis bullosa acquisita: vertical transfer of maternal autoantibody from mother to infant. Arch Dermatol 147:337–341. doi: 10.1001/archdermatol.2010.317 PubMedCrossRefGoogle Scholar
  2. Aguilar-Bryan L, Bryan J (2008) Neonatal diabetes mellitus. Endocr Rev 29:265–291PubMedCrossRefGoogle Scholar
  3. Aktas S, Colak T, Baskin E, Sevmis S, Ozdemir H, Moray G, Karakayali H, Haberal M (2011) Comparison of basiliximab and daclizumab with triple immunosuppression in renal transplantation. Transplant Proc 43:453–457. doi: 10.1016/j.transproceed.2011.01.075 PubMedCrossRefGoogle Scholar
  4. Alegre ML, Frauwirth KA, Thomson CB (2001) T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 1:220–228. doi: 10.1038/35105024 PubMedCrossRefGoogle Scholar
  5. Amato MP, Portaccio E, Ghezzi A, Hakiki B, Zipoli V, Martinelli V, Moiola L, Patti F, La Mantia L, Mancardi GL, Solaro C, Tola MR, Pozzilli C, De Giglio L, Totaro R, Lugaresi A, Di Tommaso V, Paolicelli D, Marrosu MG, Comi G, Pellegrini F, Trojano M, MS Study Group of the Italian Neurological Society (2010) Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis. Neurology 75:1794–1802. doi: 10.1212/WNL.0b013e3181fd62bb PubMedCrossRefGoogle Scholar
  6. Ansell SM, Horwitz SM, Engert A, Khan KD, Lin T, Strair R, Keler T, Graziano R, Blanset D, Yellin M, Fischkoff S, Assad A, Borchmann P (2007) Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 25:2764–2769. doi: 10.1200/JCO.2006.07.8972 PubMedCrossRefGoogle Scholar
  7. Arad I, Bar-Oz B, Ergaz Z, Nir A, Barak V (2010) Interleukin-6 and N-terminal pro-brain natriuretic peptide cord blood levels in premature infants: correlations with perinatal variables. Isr Med Assoc J 12:419–423PubMedGoogle Scholar
  8. Armstrong A, Eck SL (2003) EpCAM: a new therapeutic target for an old cancer antigen. Cancer Biol Ther 2:320–326., ReviewGoogle Scholar
  9. Arsenescu R, Arsenescu V, de Villiers WJ (2011) TNF-α and the development of the neonatal immune system: implications for inhibitor use in pregnancy. Am J Gastroenterol 106:559–562. doi: 10.1038/ajg.2011.5 PubMedCrossRefGoogle Scholar
  10. Avcin T (2008) Antiphospholipid syndrome in children. Curr Opin Rheumatol 20:595–600, ReviewPubMedCrossRefGoogle Scholar
  11. Bacquet-Deschryver H, Jouen F, Quillard M, Ménard JF, Goëb V, Lequerré T, Mejjad O, Daragon A, Tron F, Le Loët X, Vittecoq O (2008) Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. J Clin Immunol 28:445–455. doi: 10.1007/s10875-008-9214-3 PubMedCrossRefGoogle Scholar
  12. Bahadur A, Gupta N, Deka D, Mittal S (2009) Successful maternal and fetal outcome of Guillain-Barré syndrome complicating pregnancy. Indian J Med Sci 63:517–518. doi: 10.4103/0019-5359.58882 PubMedCrossRefGoogle Scholar
  13. Bahri R, Naji A, Menier C, Charpentier B, Carosella ED, Rouas-Freiss N, Durrbach A (2009) Dendritic cells secrete the immunosuppressive HLA-G molecule upon CTLA4-Ig treatment: implication in human renal transplant acceptance. J Immunol 183:7054–7062. doi: 10.4049/jimmunol.0803054 PubMedCrossRefGoogle Scholar
  14. Barbosa BF, Silva DA, Costa IN, Mineo JR, Ferro EA (2008) BeWo trophoblast cell susceptibility to Toxoplasma gondii is increased by interferon-gamma, interleukin-10 and transforming growth factor-beta1. Clin Exp Immunol 151:536–545. doi: 10.1111/j.1365-2249.2007.03583.x PubMedCrossRefGoogle Scholar
  15. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ (2007) Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66:921–926. doi: 10.1136/ard.2006.065615 PubMedCrossRefGoogle Scholar
  16. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel SO, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ (2010) Anti-infliximab and antiadalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-TNF naive patients: a cohort study. Ann Rheum Dis 69:817–821. doi: 10.1136/ard.2009.112847 PubMedCrossRefGoogle Scholar
  17. Becker C, Wirtz S, Blessing M, Pirhonen J, Strand D, Bechthold O, Frick J, Galle PR, Autenrieth I, Neurath MF (2003) Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J Clin Invest 112:693–706. doi: 10.1172/JCI200317464 Google Scholar
  18. Beckermann BM, Kallifatidis G, Groth A, Frommhold D, Apel A, Mattern J, Salnikov AV, Moldenhauer G, Wagner W, Diehlmann A, Saffrich R, Schubert M, Ho AD, Giese N, Büchler MW, Friess H, Büchler P, Herr I (2008) VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br J Cancer 99:622–631. doi: 10.1038/sj.bjc.6604508 PubMedCrossRefGoogle Scholar
  19. Béhin A, Mayer M, Kassis-Makhoul B, Espil-Taris C, Ferrer X, Chatenoud L, Laforêt P, Eymard B (2008) Severe neonatal myasthenia due to maternal anti-MuSK antibodies. Neuromuscul Disord 18:443–446. doi: 10.1016/j.nmd.2008.03.006 PubMedCrossRefGoogle Scholar
  20. Bellisai F, Morozzi G, Marcolongo R, Galeazzi M (2004) Pregnancy in Wegener’s granulomatosis: successful treatment with intravenous immunoglobulin. Clin Rheumatol 23:533–535PubMedCrossRefGoogle Scholar
  21. Bengtsson C, Andersson SE, Edvinsson L, Edvinsson ML, Sturfelt G, Nived O (2010a) Effect of medication on microvascular vasodilatation in patients with systemic lupus erythematosus. Basic Clin Pharmacol Toxicol 107:919–924. doi: 10.1111/j.1742-7843.2010.00604.x PubMedCrossRefGoogle Scholar
  22. Bengtsson C, Kapetanovic MC, Källberg H, Sverdrup B, Nordmark B, Klareskog L, Alfredsson L, EIRA Study Group (2010b) Common vaccinations among adults do not increase the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis 69:1831–1833. doi: 10.1136/ard.2010.129908 PubMedCrossRefGoogle Scholar
  23. Blank M, Shoenfeld Y (2004) Antiphospholipid syndrome infectious origin. J Clin Immunol 24:12–23. doi: 10.1023/B:JOCI.0000018058.28764.ce PubMedCrossRefGoogle Scholar
  24. Blois SM, Ilarregui JM, Tometten M, Garcia M, Orsal AS, Cordo-Russo R, Toscano MA, Bianco GA, Kobelt P, Handjiski B, Tirado I, Markert UR, Klapp BF, Poirier F, Szekeres-Bartho J, Rabinovich GA, Arck PC (2007) A pivotal role for galectin-1 in fetomaternal tolerance. Nat Med 13:1450–1457. doi: 10.1038/nm1680 PubMedCrossRefGoogle Scholar
  25. Bokemeyer C (2010) Catumaxomab-trifunctional anti-EpCAM antibody used to treat malignant ascites. Expert Opin Biol Ther 10:1259–1269. doi: 10.1517/14712598.2010.504706, ReviewPubMedCrossRefGoogle Scholar
  26. Bonnefond A, Durand E, Sand O, De Graeve F, Gallina S, Busiah K, Lobbens S, Simon A, Bellanné-Chantelot C, Létourneau L, Scharfmann R, Delplanque J, Sladek R, Polak M, Vaxillaire M, Froguel P (2010) Molecular diagnosis of neonatal diabetes mellitus using next-generation sequencing of the whole exome. PLoS One 5:e13630. doi: 10.1371/journal.pone.0013630 PubMedCrossRefGoogle Scholar
  27. Bosani M, Ardizzone S, Porro GB (2009) Biologic targeting in the treatment of inflammatory bowel diseases. Biologics 3:77–97PubMedGoogle Scholar
  28. Bottomley A, Debruyne C, Felip E, Millward M, Thiberville L, D’Addario G, Rome L, Zatloukal P, Coens C, Giaccone G (2008) Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer. Eur J Cancer 44:2178–2184. doi: 10.1016/j.ejca.2008.06.036 PubMedCrossRefGoogle Scholar
  29. Bouché O, Brixi-Benmansour H, Bertin A, Perceau G, Lagarde S (2005) Trichomegaly of the eyelashes following treatment with cetuximab. Ann Oncol 16:1711–1712. doi: 10.1093/annonc/mdi300 PubMedCrossRefGoogle Scholar
  30. Boukhvalova MS, Prince GA, Soroush L, Harrigan DC, Vogel SN, Blanco JC (2006) The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease. Vaccine 24:5027–5035. doi: 10.1016/j.vaccine.2006.03.064 PubMedCrossRefGoogle Scholar
  31. Brucato A, Ramoni V, Penco S, Sala E, Buyon J, Clancy R (2010) Passively acquired anti-SSA/Ro antibodies are required for congenital heart block following ovodonation but maternal genes are not. Arthritis Rheum 62:3119–3121. doi: 10.1002/art.27575 PubMedCrossRefGoogle Scholar
  32. Brucato A, Ramoni V, Gerosa M, Pisoni MP (2011) Congenital fetal heart block: a potential therapeutic role for intravenous immunoglobulin. Obstet Gynecol 117:177. doi: 10.1097/AOG.0b013e3182042972 PubMedCrossRefGoogle Scholar
  33. Buchwald B, Toyka KV, Zielasek J, Weishaupt A, Schweiger S, Dudel J (1998) Neuromuscular blockade by IgG antibodies from patients with Guillain-Barré syndrome: a macro-patch-clamp study. Ann Neurol 44:913–922. doi: 10.1002/ana.410440610 PubMedCrossRefGoogle Scholar
  34. Buchwald B, de Baets M, Luijckx GJ, Toyka KV (1999) Neonatal Guillain-Barré syndrome: blocking antibodies transmitted from mother to child. Neurology 53:1246–1253PubMedGoogle Scholar
  35. Bustamante-Aragones A, Trujillo-Tiebas MJ, Gallego-Merlo J, Rodriguezde Alba M, Gonzalez-Gonzalez C, Cantalapiedra D, Ayuso C, Ramos C (2008) Prenatal diagnosis of Huntington disease in maternal plasma: direct and indirect study. Eur J Neurol 15:1338–1344. doi: 10.1111/j.1468-1331.2008.02312.x PubMedCrossRefGoogle Scholar
  36. Canti V, Castiglioni MT, Rosa S, Franchini S, Sabbadini MG, Manfredi AA, Rovere-Querini P (2011) Pregnancy outcomes in patients with systemic autoimmunity. Autoimmunity 45(2):169–175. doi: 10.3109/08916934.2011.593600 PubMedCrossRefGoogle Scholar
  37. Carneiro-Sampaio M, Liphaus BL, Jesus AA, Silva CA, Oliveira JB, Kiss MH (2008) Understanding systemic lupus erythematosus physiopathology in the light of primary immunodeficiencies. J Clin Immunol 28(Suppl 1):S34–S41. doi: 10.1007/s10875-008-9187-2, ReviewPubMedCrossRefGoogle Scholar
  38. Carter JD, Valeriano J, Vasey FB (2006) Tumor necrosis factor-a inhibition and VATER association: a causal relationship? Case report. J Rheumatol 33:1014–1017PubMedGoogle Scholar
  39. Carter JD, Ladhani A, Ricca L, Valeriano J, Vasey FB (2009) A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 36:635–641. doi: 10.3899/jrheum.080545 PubMedCrossRefGoogle Scholar
  40. Casadevall A (1999) Passive antibody therapies: progress and continuing challenges. Clin Immunol 93:5–15. doi: 10.1006/clim.1999.4768 PubMedCrossRefGoogle Scholar
  41. Casadevall A (2006) The third age of antimicrobial therapy. Clin Infect Dis 42:1414–1416. doi: 10.1086/503431 PubMedCrossRefGoogle Scholar
  42. Chakravarty EF, Murray ER, Kelman A, Farmer P (2011) Pregnancy outcomes after maternal exposure to rituximab. Blood 117:1499–1506. doi: 10.1182/blood-2010-07-295444 PubMedCrossRefGoogle Scholar
  43. Challis JR, Lockwood CJ, Myatt L, Norman JE, Strauss JF 3rd, Petraglia F (2009) Inflammation and pregnancy. Reprod Sci 16:206–215. doi: 10.1177/1933719108329095 PubMedCrossRefGoogle Scholar
  44. Champlin R, Ho W, Gajewski J, Feig S, Burnison M, Holley G, Greenberg P, Lee K, Schmid I, Giorgi J, Yam P, Petz L, Winston D, Warner N, Reichertet T (1990) Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood 76:418–423PubMedGoogle Scholar
  45. Chao MM, Levine JE, Ferrara JL, Cooling L, Cooke KR, Hutchinson RJ, Yanik GA (2008) Successful treatment of refractory immune hemolysis following unrelated cord blood transplant with Campath-1H. Pediatr Blood Cancer 50:917–919. doi: 10.1002/pbc.21187 PubMedCrossRefGoogle Scholar
  46. Chatenoud L, Bluestone JA (2007) CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 7:622–632. doi: 10.1038/nri2134, ReviewPubMedCrossRefGoogle Scholar
  47. Chen XX, Gu YY, Li SJ, Qian J, Hwang KK, Chen PP, Chen SL, Yang CD (2007) Some plasmin-induced antibodies bind to cardiolipin, display lupus anticoagulant activity and induce fetal loss in mice. J Immunol 178:5351–5356PubMedGoogle Scholar
  48. Chen CH, Liao HT, Chen HA, Liu CH, Liang TH, Wang CT, Tsai CY, Chou CT (2010) Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-alpha blocker therapy. Rheumatology (Oxford) 49:264–270. doi: 10.1093/rheumatology/kep360 CrossRefGoogle Scholar
  49. Chou AK, Hsieh SC, Su YN, Jeng SF, Chen CY, Chou HC, Tsao PN, Hsieh WS (2009) Neonatal and pregnancy outcome in primary antiphospholipid syndrome: a 10-year experience in one medical center. Pediatr Neonatol 50:143–146. doi: 10.1016/S1875-9572(09)60052-8 PubMedCrossRefGoogle Scholar
  50. Clark CA, Spitzer KA, Laskin CA (2005) Decrease in pregnancy loss rates in patients with systemic lupus erythematosus over a 40-year period. J Rheumatol 32:1709–1712PubMedGoogle Scholar
  51. Clark CA, Spitzer KA, Laskin CA, Crowther MR, Ginsberg JS (2010) Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss. Obstet Gynecol 116:997–998. doi: 10.1097/AOG.0b013e3181f4e012 PubMedCrossRefGoogle Scholar
  52. Clement LT, Grossi CE, Gartland GL (1984) Morphologic and phenotypic features of the subpopulation of Leu-2+ cells that suppresses B cell differentiation. J Immunol 133:2461–2468PubMedGoogle Scholar
  53. Clowse ME (2010) The use of anti-TNFα medications for rheumatologic disease in pregnancy. Int J Women Health 2:199–209CrossRefGoogle Scholar
  54. Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P (2009) Safety and tolerability of omalizumab. Clin Exp Allergy 39:788–797. doi: 10.1111/j.1365-2222.2009.03214.x, ReviewPubMedCrossRefGoogle Scholar
  55. Couriel DR, Saliba R, de Lima M, Giralt S, Andersson B, Khouri I, Hosing C, Ippoliti C, Shpall EJ, Champlin R, Alousi A (2009) A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow Transpl 15:1555–1562. doi: 10.1016/j.bbmt.2009.08.003 CrossRefGoogle Scholar
  56. Coussons-Read ME, Mazzeo RS, Whitford MH, Schmitt M, Moore LG, Zamudio S (2002) High altitude residence during pregnancy alters cytokine and catecholamine levels. Am J Reprod Immunol 48:344–354. doi: 10.1034/j.1600-0897.2002.01078.x PubMedCrossRefGoogle Scholar
  57. Csáky K, Do DV (2009) Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. Am J Ophthalmol 148:647–656PubMedCrossRefGoogle Scholar
  58. Curtis BR (2008) Genotyping for human platelet alloantigen polymorphisms: applications in the diagnosis of alloimmune platelet disorders. Semin Thromb Hemost 34:539–548. doi: 10.1055/s-0028-1103365 PubMedCrossRefGoogle Scholar
  59. Dadhwal V, Sharma AK, Deka D, Gupta B, Mittal S (2011) The obstetric outcome following treatment in a cohort of patients with antiphospholipid antibody syndrome in a tertiary care center. J Postgrad Med 57:16–19. doi: 10.4103/0022-3859.74285 PubMedCrossRefGoogle Scholar
  60. Dammacco F, Tucci FA, Lauletta G, Gatti P, De Re V, Conteduca V, Sansonno S, Russi S, Mariggiò MA, Chironna M, Sansonno D (2010) Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 116:343–353. doi: 10.1182/blood-2009-10-245878 PubMedCrossRefGoogle Scholar
  61. Danilov AV, Brodsky RA, Craigo S, Smith H, Miller KB (2010) Managing a pregnant patient with paroxysmal nocturnal hemoglobinuria in the era of eculizumab. Leuk Res 34:566–571. doi: 10.1016/j.leukres.2009.10.025 PubMedCrossRefGoogle Scholar
  62. Dávila RD, Julian CG, Wilson MJ, Browne VA, Rodriguez C, Bigham AW, Shriver MD, Vargas E, Moore LG (2011) Do cytokines contribute to the Andean-associated protection from reduced fetal growth at high altitude? Reprod Sci 18:79–87PubMedCrossRefGoogle Scholar
  63. De Propris MS, Raponi S, Diverio D, Milani ML, Meloni G, Falini B, Foa’ R, Guarini A (2011) High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation. Haematologica 96(10):1548–1551. doi: 10.3324/haematol.2011.043786 PubMedCrossRefGoogle Scholar
  64. Dekker MJ, van den Akker EL, Koper JW, Manenschijn L, Geleijns K, Ruts L, van Rijs W, Tio-Gillen AP, van Doorn PA, Lamberts SW, Jacobs BC (2009) Effect of glucocorticoid receptor gene polymorphisms in Guillain-Barré syndrome. J Peripher Nerv Syst 14:75–83. doi: 10.1111/j.1529-8027.2009.00216.x PubMedCrossRefGoogle Scholar
  65. D’Haens G, Daperno M (2006) Advances in biologic therapy for ulcerative colitis and Crohn’s disease. Curr Gastroenterol Rep 8:506–512. doi: 10.1007/s11894-006-0041-5 PubMedCrossRefGoogle Scholar
  66. Djokanovic N, Klieger-Grossmann C, Pupco A, Koren G (2011) Safety of infliximab use during pregnancy. Reprod Toxicol 32:93–97. doi: 10.1016/j.reprotox.2011.05.009 PubMedCrossRefGoogle Scholar
  67. Dong T, Moran E, Vinh Chau N, Simmons C, Luhn K, Peng Y, Wills B, Dung NP, Thao LTT, Hien TT, McMichael A, Farrar J, Rowland-Joneset S (2007) High pro-inflammatory cytokine secretion and loss of high avidity cross-reactive cytotoxic T-cells during the course of secondary dengue virus infection. PLoS One 2(12):e1192. doi: 10.1371/journal.pone.000119 PubMedCrossRefGoogle Scholar
  68. Dowdle WR, Sarateanu D, Reimer CB (1972) Antiantibody enhancement of hemagglutination inhibition by influenza anti-neuraminidase. J Immunol 109:1321–1326PubMedGoogle Scholar
  69. Durrant LG, Maxwell-Armstrong C, Buckley D, Amin S, Robins RA, Carmichael J, Scholefield JH (2000) A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55. Clin Cancer Res 6:422–430. doi:10.1002/(SICI)1097-0215(20000101)85:1<87::AID-IJC16>3.0.CO;2-KPubMedGoogle Scholar
  70. Edula RGR, Picco MF (2009) An evidence-based review of natalizumab therapy in the management of Crohn’s disease. Ther Clin Risk Manage 5:935–942, ReviewGoogle Scholar
  71. Efthimiou P, Georgy S (2006) Pathogenesis and management of adult-onset Still’s disease. Semin Arthritis Rheum 36:144–152. doi: 10.1016/j.semarthrit.2006.07.001 PubMedCrossRefGoogle Scholar
  72. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C (2004) Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF alpha therapy. J Exp Med 200:277–285. doi: 10.1084/jem.20040165 PubMedCrossRefGoogle Scholar
  73. Elimelakh M, Dayton V, Park KS, Gruessner AC, Sutherland D, Howe RB, Reding MT, Eastlund T, van Burik JA, Singleton TP, Gruessner RW, Key NS (2007) Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients. Haematologica 92:1029–1036. doi: 10.3324/haematol.10733 PubMedCrossRefGoogle Scholar
  74. Emery P, Durez P, Dougados M, Legerton CW, Becker J-C, Vratsanos G, Genant HK, Peterfy C, Mitra P, Overfield S, Qi K, Westhovens R (2010) Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis 69:510–516. doi: 10.1136/ard.2009.119016 PubMedCrossRefGoogle Scholar
  75. Evoli A (2010) Acquired myasthenia gravis in childhood. Curr Opin Neurol 23:536–540. doi: 10.1097/WCO.0b013e32833c32af, ReviewPubMedCrossRefGoogle Scholar
  76. Fanale MA, Younes A (2007) Monoclonal antibodies in the treatment of non-Hodgkin’s lymphoma. Drugs 67:333–350. doi: 10.2165/00003495-200767030-00002, ReviewPubMedCrossRefGoogle Scholar
  77. Ferenczi E, Bán E, Abrahám A, Kaposi T, Petrányi G, Berencsi G, Vaheri A (2008) Severe tick-borne encephalitis in a patient previously infected by West Nile virus. Scand J Infect Dis 40:759–761. doi: 10.1080/00365540801995386 PubMedCrossRefGoogle Scholar
  78. Fernandez LE, Gabri MR, Guthmann MD, Gomez RE, Gold S, Fainboim L, Gomez DE, Alonso DF (2010) NGcGM3 ganglioside: a privileged target for cancer vaccines. Clin Dev Immunol 2010:814397PubMedCrossRefGoogle Scholar
  79. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676. doi: 10.1038/nm0603-669 PubMedCrossRefGoogle Scholar
  80. Ferrara N, Damico L, Shams N, Lowman H, Kim R (2006) Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26:859–870. doi: 10.1097/01.iae.0000242842.14624.e7, ReviewPubMedCrossRefGoogle Scholar
  81. Foon KA, John WJ, Chakraborty M, Das R, Teitelbaum A, Garrison J, Kashala O, Chatterjee SK, Bhattacharya-Chatterjee M (1999) Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol 17:2889–2895PubMedGoogle Scholar
  82. Foon KA, Lutzky J, Baral RN, Yannelli JR, Hutchins L, Teitelbaum A, Kashala OL, Das R, Garrison J, Reisfeld RA, Bhattacharya-Chatterjee M (2000) Clinical and immune responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J Clin Oncol 18:376–384PubMedGoogle Scholar
  83. Förger F, Østensen M (2010) Is IgG galactosylation the relevant factor for pregnancy-induced remission of rheumatoid arthritis? Arthritis Res Ther 12:108. doi: 10.1186/ar2919 PubMedCrossRefGoogle Scholar
  84. Forthal DN, Moog C (2009) Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS 4:388–393. doi: 10.1097/COH.0b013e32832f0a89, ReviewPubMedCrossRefGoogle Scholar
  85. Fouache D, Goëb V, Massy-Guillemant N, Avenel G, Bacquet-Deschryver H, Kozyreff-Meurice M, Ménard JF, Muraine M, Savoye G, Le Loët X, Tharasse C, Vittecoq O (2009) Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology (Oxford) 48:761–764. doi: 10.1093/rheumatology/kep083 CrossRefGoogle Scholar
  86. Friedman DM, Llanos C, Izmirly PM, Brock B, Byron J, Copel J, Cummiskey K, Dooley MA, Foley J, Graves C, Hendershott C, Kates R, Komissarova EV, Miller M, Paré E, Phoon CK, Prosen T, Reisner D, Ruderman E, Samuels P, Yu JK, Kim MY, Buyon JP (2010) Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum 62:1138–1146. doi: 10.1002/art.27308 PubMedCrossRefGoogle Scholar
  87. Friedrichs B, Tiemann M, Salwender H, Verpoort K, Wenger MK, Schmitz N (2006) The effects of rituximab treatment during pregnancy on a neonate. Haematologica 91:1426–1427PubMedGoogle Scholar
  88. Frosch M, Ahlmann M, Vogl T, Wittkowski H, Wulffraat N, Foell D, Roth J (2009) The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 60:883–891. doi: 10.1002/art.24349 PubMedCrossRefGoogle Scholar
  89. Gall B, Yee A, Berry B, Birchman D, Hayashi A, Dansereau J, Hart J (2010) Rituximab for management of refractory pregnancy-associated immune thrombocytopenic purpura. J Obstet Gynaecol Can 32:1167–1171PubMedGoogle Scholar
  90. Garrido G, Lorenzano P, Sánchez B, Beausoleil I, Alonso DF, Pérez R, Fernández LE (2007) T cells are crucial for the anti-metastatic effect of anti-epidermal growth factor receptor antibodies. Cancer Immunol Immunother 56:1701–1710. doi: 10.1007/s00262-007-0313-4 PubMedCrossRefGoogle Scholar
  91. Gasim T (2011) Immune thrombocytopenic purpura in pregnancy: a reappraisal of obstetric management and outcome. J Reprod Med 56:163–168PubMedGoogle Scholar
  92. Geleijns K, Emonts M, Laman JD, van Rijs W, van Doorn PA, Hermans PW, Jacobs BC (2007) Genetic polymorphisms of macrophage-mediators in Guillain-Barré syndrome. J Neuroimmunol 190:127–130. doi: 10.1016/j.jneuroim.2007.07.008 PubMedCrossRefGoogle Scholar
  93. Ghevaert C, Wilcox DA, Fang J, Armour KL, Clark MR, Ouwehand WH, Williamson LM (2008) Developing recombinant HPA-1a-specific antibodies with abrogated Fcg receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia. J Clin Invest 118:2929–2938PubMedGoogle Scholar
  94. Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M, Thiberville L, D’Addario G, Coens C, Rome LS et al (2005) Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971–08971B; Silva Study). J Clin Oncol 23:6854–6864. doi: 10.1200/JCO.2005.17.186 PubMedCrossRefGoogle Scholar
  95. Gibbs JD, Ornoff DM, Igo HA, Zeng JY, Imani F (2009) Cell cycle arrest by transforming growth factor beta1 enhances replication of respiratory syncytial virus in lung epithelial cells. J Virol 83:12424–12431. doi: 10.1128/JVI.00806-09 Google Scholar
  96. Goldfinger S (2009) The inherited autoinflammatory syndrome: a decade of discovery. Trans Am Clin Climatol Assoc 120:413–418, ReviewPubMedGoogle Scholar
  97. Goyal V, Misra BK, Singh S, Prasad K, Behari M (2004) Acute inflammatory demyelinating polyneuropathy in patients with pregnancy. Neurol India 52:283–284PubMedGoogle Scholar
  98. Groothuis JR, Hoopes JM, Hemming VG (2011) Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis. Adv Ther 28:110–125. doi: 10.1007/s12325-010-0101-y PubMedCrossRefGoogle Scholar
  99. Guthmann MD, Castro MA, Cinat G, Venier C, Koliren L, Bitton RJ, VÃzquez AM, Fainboim L (2006) Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients. J Immunother 29:215–223Google Scholar
  100. Hall ZW, Gorin PD, Silberstein L, Bennett C (1985) A postnatal change in the immunological properties of the acetylcholine receptor at rat muscle endplates. J Neurosci 5:730–734PubMedGoogle Scholar
  101. Hament JM, Aerts PC, Fleer A, van Dijk H, Harmsen T, Kimpen JL, Wolfs TF (2005) Direct binding of respiratory syncytial virus to pneumococci: a phenomenon that enhances both pneumococcal adherence to human epithelial cells and pneumococcal invasiveness in a murine model. Pediatr Res 58:1198–1203. doi: 10.1203/01.pdr.0000188699.55279.1b PubMedCrossRefGoogle Scholar
  102. Haney M, Kosten TR (2004) Therapeutic vaccines for substance dependence. Expert Rev Vaccines 3:11–18. doi: 10.1586/14760584.3.1.11, ReviewPubMedCrossRefGoogle Scholar
  103. He J, Yin Y, Luster TA, Watkins L, Thorpe PE (2009) Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma. Clin Cancer Res 15(22):6871–6880. doi: 10.1158/1078-0432.CCR-09-1499, 15 Nov 2009
  104. Hellwig K, Haghikia A, Gold R (2010) Parenthood and immunomodulation in patients with multiple sclerosis. J Neurol 257:580–583. doi: 10.1007/s00415-009-5376-z PubMedCrossRefGoogle Scholar
  105. Hemminki K, Li X, Sundquist J, Sundquist K (2010) The epidemiology of Graves’ disease: evidence of a genetic and an environmental contribution. J Autoimmun 34:J307–J313. doi: 10.1016/j.jaut.2009.11.019 PubMedCrossRefGoogle Scholar
  106. Hernández AM, Toledo D, Martínez D, Griñán T, Brito V, Macías A, Alfonso S, Rondón T, Suárez E, Vázquez AM, Pérez R (2008) Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J Immunol 181:6625–6634PubMedGoogle Scholar
  107. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346:1692–1698. doi: 10.1056/NEJMoa012864 PubMedCrossRefGoogle Scholar
  108. Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestoneet JA (2005) A single course of anti-CD3 monoclonal antibody hOKT3γ1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54:1763–1769. doi: 10.2337/diabetes.54.6.1763 PubMedCrossRefGoogle Scholar
  109. Hesselmans LF, Jennekens FG, Van den Oord CJ, Veldman H, Vincent A (1993) Development of innervation of skeletal muscle fibers in man: relation to acetylcholine receptors. Anat Rec 236:553–562. doi: 10.1002/ar.1092360315 PubMedCrossRefGoogle Scholar
  110. Holgate ST, Djukanović R, Casale T, Bousquet J (2005) Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy 35:408–416. doi: 10.1111/j.1365-2222.2005.02191.x, ReviewPubMedCrossRefGoogle Scholar
  111. Houot R, Levy R (2009) Vaccines for lymphomas: idiotype vaccines and beyond. Blood Rev 23:137–142. doi: 10.1182/blood-2009-05-223958 PubMedCrossRefGoogle Scholar
  112. Houot R, Kohrt H, Goldstein MJ, Levy R (2011) Immunomodulating antibodies and drugs for the treatment of hematological malignancies. Cancer Metastasis Rev 30:97–109. doi: 10.1007/s10555-011-9274-3 PubMedCrossRefGoogle Scholar
  113. Jadaon J, Shushan A, Ezra Y, Sela HY, Ozcan C, Rojansky N (2005) Behçet’s disease and pregnancy. Acta Obstet Gynecol Scand 84:939–944. doi: 10.1080/j.0001-6349.2005.00761.x, ReviewPubMedGoogle Scholar
  114. Jesus AA, Oliveira JB, Hilário MO, Terreri MT, Fujihira E, Watase M, Carneiro-Sampaio M, Silva CA (2010) Pediatric hereditary autoinflammatory syndromes. J Pediatr (Rio J) 86:353–366. doi: 10.2223/JPED.2015, ReviewGoogle Scholar
  115. Jin LP, Zhou YH, Wang MY, Zhu XY, Li DJ (2005) Blockade of CD80 and CD86 at the time of implantation inhibits maternal rejection to the allogeneic fetus in abortion-prone matings. J Reprod Immunol 65:133–146. doi: 10.1016/j.jri.2004.08.009 PubMedCrossRefGoogle Scholar
  116. Johnson TR, Graham BS (2004) Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection. Pediatr Infect Dis J 23(Suppl):S46–S57. doi: 10.1097/01.inf.0000108192.94692.d2, ReviewPubMedCrossRefGoogle Scholar
  117. Jørgensen KT, Pedersen BV, Nielsen NM, Jacobsen S, Frisch M (2011) Childbirths and risk of female predominant and other autoimmune diseases in a population-based Danish cohort. J Autoimmun. 1 Aug 2011Google Scholar
  118. Just J, Sahraoui F, Le Gros V, Grimfeld A, Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C (2007) Effectiveness of omalizumab in monozygotic twin sisters with severe allergic asthma. Allergy 62:453–454. doi: 10.1111/j.1398-9995.2006.01314.x PubMedCrossRefGoogle Scholar
  119. Kane SV, Acquah LA (2009) Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol 104:228–233. doi: 10.1038/ajg.2008.71 PubMedCrossRefGoogle Scholar
  120. Katsumi Y, Kuwahara Y, Tamura S, Kikuchi K, Otabe O, Tsuchiya K, Iehara T, Kuroda H, Hosoi H, Sugimoto T (2008) Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity. Clin Cancer Res 14:1192–1199. doi: 10.1158/1078-0432.CCR-07-1661 PubMedCrossRefGoogle Scholar
  121. Kaufman KA, Bowen JA, Tsai AF, Bluestone JA, Hunt JS, Ober C (1999) The CTLA-4 gene is expressed in placental fibroblasts. Mol Hum Reprod 5:84–87. doi: 10.1093/molehr/5.1.84 PubMedCrossRefGoogle Scholar
  122. Kelly R, Arnold L, Richards S, Hill A, Bomken C, Hanley J, Loughney A, Beauchamp J, Khursigara G, Rother RP, Chalmers E, Fyfe A, Fitzsimons E, Nakamura R, Gaya A, Risitano AM, Schubert J, Norfolk D, Simpson N, Hillmen P (2010) The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol 149:446–450. doi: 10.1111/j.1365-2141.2010.08099.x PubMedCrossRefGoogle Scholar
  123. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin J-M, De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach J-F, Pipeleers D, Chatenoud L (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352:2598–2608. doi: 10.1056/NEJMoa043980 PubMedCrossRefGoogle Scholar
  124. Kitzmiller JL (1978) Autoimmune disorders: maternal, fetal, and neonatal risks. Clin Obstet Gynecol 21:385–396. doi: 10.1097/00003081-197806000-00012 PubMedCrossRefGoogle Scholar
  125. Klareskog L, Gregersen PK, Huizinga TW (2010) Prevention of autoimmune rheumatic disease: state of the art and future perspectives. Ann Rheum Dis 69:2062–2066. doi: 10.1136/ard.2010.142109, ReviewPubMedCrossRefGoogle Scholar
  126. Klausz K, Berger S, van Bueren JJ Lammerts, Derer S, Lohse S, Dechant M, van de Winkel JG, Peipp M, Parren PW, Valerius T (2011) Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII). Cancer Sci 102(10):1761–1768. doi: 10.1111/j.1349-7006.2011.02019.x PubMedCrossRefGoogle Scholar
  127. Kleinschmidt-DeMasters BK, Tyler KL (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353:369–374. doi: 10.1056/NEJMoa051782 PubMedCrossRefGoogle Scholar
  128. Klimm B, Schnell R, Diehl V, Engert A (2005) Current treatment and immunotherapy of Hodgkin's lymphoma. Haematologica 90:1680–1692Google Scholar
  129. Klink DT, van Elburg RM, Schreurs MW, van Well GT (2008) Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol 2008:271363. doi: 10.1155/2008/271363 PubMedCrossRefGoogle Scholar
  130. Köhler H (1978) Regulation of immune response by anti-receptor antibody. Ann Clin Lab Sci 8:318–322PubMedGoogle Scholar
  131. Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Müller A, Pachynski R, Czerwinski D, Coutre S, Chao MP, Chen L, Tedder TF, Levy R (2011) D137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 117:2423–2432. doi: 10.1182/blood-2010-08-301945 PubMedCrossRefGoogle Scholar
  132. Kothary N, Diak IL, Brinker A, Bezabeh S, Avigan M, Pan GD (2011) Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol 65:546. doi: 10.1016/j.jaad.2010.05.033 PubMedCrossRefGoogle Scholar
  133. Koukoura O, Mantas N, Linardakis H, Hajiioannou J, Sifakis S (2008) Successful term pregnancy in a patient with Wegener’s granulomatosis: case report and literature review. Fertil Steril 89:457.e1–457.e5. doi: 10.1016/j.fertnstert.2007.03.054, ReviewCrossRefGoogle Scholar
  134. Krapf R, Zimmermann A, Stocker F (1981) Lethal vasculitis of coronary arteries in a neonate and two infants: possible neonatal variant of the MLNS/IPN complex? Helv Paediatr Acta 36:589–598PubMedGoogle Scholar
  135. Krupitskaya Y, Wakelee HA (2009) Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Curr Opin Investig Drugs 10:597–605PubMedGoogle Scholar
  136. Kuenen B, Witteveen PO, Ruijter R, Giaccone G, Dontabhaktuni A, Fox F, Katz T, Youssoufian H, Zhu J, Rowinsky EK, Voest EE (2010) A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin Cancer Res 16:1915–1923. doi: 10.1158/1078-0432.CCR-09-2425 PubMedCrossRefGoogle Scholar
  137. Kulkarni S, Reddy KB, Esteva FJ, Moore HC, Budd GT, Tubbs RR (2010) Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer. Oncogene 29:1339–1350PubMedCrossRefGoogle Scholar
  138. Ladjemi MZ, Chardes T, Corgnac S, Garambois V, Morisseau S, Robert B, Bascoul-Mollevi C, Ait Arsa I, Jacot W, Pouget JP, Pelegrin A, Navarro-Teulon I (2011) Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice. Breast Cancer Res 13:R17. doi: 10.1186/bcr2826 PubMedCrossRefGoogle Scholar
  139. Lee LA (1990) Maternal autoantibodies and pregnancy. II. The neonatal lupus syndrome. Baillieres Clin Rheumatol 4:69–84. doi: 10.1016/S0950-3579(05)80244-4 PubMedCrossRefGoogle Scholar
  140. Lee J, Lee EN, Kim EY, Park HJ, Chang CY, Jung DY, Choi SY, Lee SK, Lee KW, Kwon GY, Joh JW, Kim SJ (2005) Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease. Immunol Lett 101:210–216. doi: 10.1016/j.imlet.2005.06.001 PubMedCrossRefGoogle Scholar
  141. Lee HJ, Gulbis A, De Padua SL, Hosing C, Khouri I, de Lima M, Champlin RE, Ciurea SO (2008a) Rituximab for passenger lymphocyte syndrome associated with allogeneic SCT. Bone Marrow Transplant 42:67–69. doi: 10.1038/bmt.2008.79 PubMedCrossRefGoogle Scholar
  142. Lee YM, Miyahara N, Takeda K, Prpich J, Oh A, Balhorn A, Joetham A, Gelfand EW, Dakhama A (2008b) IFN-gamma production during initial infection determines the outcome of reinfection with respiratory syncytial virus. Am J Respir Crit Care Med 177:208–218PubMedCrossRefGoogle Scholar
  143. Leonard JP, Schuster SJ, Emmanouilides C, Couture F, Teoh N, Wegener WA, Coleman M, Goldenberg DM (2008) Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 113:2714–2723. doi: 10.1002/cncr.23890 PubMedCrossRefGoogle Scholar
  144. Libraty DH, Acosta LP, Tallo V, Segubre-Mercado E, Bautista A, Potts JA, Jarman RG, Yoon IK, Gibbons RV, Brion JD, Capeding RZ (2009) A prospective nested case-control study of dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med 6:e1000171. doi: 10.1371/journal.Pmed/e1000171 PubMedCrossRefGoogle Scholar
  145. Lim CK, Sun L, Feng Q, Law P, Chua WT, Lim SN, Hwang WY (2008) Effect of anti-CD52 antibody alemtuzumab on ex-vivo culture of umbilical cord blood stem cells. J Hematol Oncol 1:19. doi: 10.1186/1756-8722-1-19 PubMedCrossRefGoogle Scholar
  146. Lima K, Abrahamsen TG, Wolff AB, Husebye E, Alimohammadi M, Kämpe O, Følling I (2011) Hypoparathyroidism and autoimmunity in the 22q11.2 deletion syndrome. Eur J Endocrinol 165:345–352. doi: 10.1530/EJE-10-1206 PubMedCrossRefGoogle Scholar
  147. Littlewood JM, Payne RB (1977) Placental transfer of IgG paraprotein with prolonged immunosuppression. Br Med J 1:291. doi: 10.1136/bmj.1.6056.291-a PubMedCrossRefGoogle Scholar
  148. Littlewood JM, Hunter I, Payne RB, Miles DW (1970) Placental transfer of an IgG paraprotein associated with prolonged immunosuppression. Br Med J 4:94–95. doi: 10.1136/bmj.4.5727.94 PubMedCrossRefGoogle Scholar
  149. Liu SC, Chang TY, Lee YJ, Chu CC, Lin M, Chen ZX, Liu HF, Dang CW, Chang SC, Lee CS, Chen TL, Huang CH (2007) Influence of HLA-DRB1 genes and the shared epitope on genetic susceptibility to rheumatoid arthritis in Taiwanese. J Rheumatol 34:674–680PubMedGoogle Scholar
  150. Ludvigsson JF, Ludvigsson J (2002) Inflammatory bowel disease in mother or father and neonatal outcome. Acta Paediatr 91:145–151. doi: 10.1111/j.1651-2227.2002.tb01686.x PubMedCrossRefGoogle Scholar
  151. Lühn K, Simmons CP, Moran E, Dung NT, Chau TN, Quyen NT, le Thao TT, Van Ngoc T, Dung NM, Wills B, Farrar J, McMichael AJ, Dong T, Rowland-Jones S (2007) Increased frequencies of CD4+ CD25(high) regulatory T cells in acute dengue infection. J Exp Med 204:979–985PubMedCrossRefGoogle Scholar
  152. Luijckx GJ, Vles J, de Baets M, Buchwald B, Troost J (1997) Guillain-Barré syndrome in mother and newborn child. Lancet 349:27. doi: 10.1016/S0140-6736(97)24001-8 PubMedCrossRefGoogle Scholar
  153. Luijten JA, Reijneveld-de Jong SD, Teerlink T, Camps VT, Osterhaus AD, UytdeHaag AG (1988) Monoclonal antibodies to P2 basic protein and their use in the investigation of some aspects of the Guillain-Barré syndrome. J Neurol Sci 86:265–276PubMedCrossRefGoogle Scholar
  154. Mack CL (2007) The pathogenesis of biliary atresia: evidence for a virus-induced autoimmune disease. Semin Liver Dis 27:233–242. doi: 10.1055/s-2007-985068 PubMedCrossRefGoogle Scholar
  155. Magnani CF, Alberigo G, Bacchetta R, Serafini G, Andreani M, Roncarolo MG, Gregori S (2011) Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cells. Eur J Immunol 41:1652–1662. doi: 10.1002/eji.201041120 PubMedCrossRefGoogle Scholar
  156. Mahic M, Skurtveit S, Selmer R, Rønning M, Furu K (2011) Prevalence, incidence and persistence of etanercept and adalimumab in Norway 2005-2009. Pharmacoepidemiol Drug Saf 20:457–463. doi: 10.1002/pds.2091 PubMedCrossRefGoogle Scholar
  157. Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen Y-F (2011) Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess 15:1–278. doi: 10.3310/hta15140 PubMedGoogle Scholar
  158. Mano Y, Shibata K, Sumigama S, Hayakawa H, Ino K, Yamamoto E, Kajiyama H, Nawa A, Kikkawa F (2009) Tocilizumab inhibits interleukin-6-mediated matrix metalloproteinase-2 and -9 secretions from human amnion cells in preterm premature rupture of membranes. Gynecol Obstet Invest 68:145–153PubMedCrossRefGoogle Scholar
  159. Martin V, Lee LA, Askanase AD, Katholi M, Buyon JP (2002) Long-term followup of children with neonatal lupus and their unaffected siblings. Arthritis Rheum 46:2377–2383. doi: 10.1002/art.10638 PubMedCrossRefGoogle Scholar
  160. Martin-Mateos MA (2007) Monoclonal antibodies in pediatrics: use in prevention and treatment. Allergol Immunopathol (Madr) 35:145–150. doi: 10.1157/13108225, ReviewCrossRefGoogle Scholar
  161. Masatlioglu S, Seyahi E, Tahir Turanli E, Fresko I, Gogus F, Senates E, Oguz Savran F, Yazici H (2010) A twin study in Behçet’s syndrome. Clin Exp Rheumatol 28(4 Suppl 60):S62–S66PubMedGoogle Scholar
  162. Matsumoto K, Shimizu C, Arao T, Andoh M, Katsumata N, Kohno T, Yonemori K, Koizumi F, Yokote H, Aogi K, Tamura K, Nishio K, Fujiwara Y (2009) Identification of predictive biomarkers for response to trastuzumab using plasma FUCA activity and N-glycan identified by MALDI-TOF-MS. J Proteome Res 8:457–462. doi: 10.1021/pr800655p PubMedCrossRefGoogle Scholar
  163. McKian KP, Haluska P (2009) Cixutumumab. Expert Opin Investig Drugs 18:1025–1033. doi: 10.1517/13543780903055049, ReviewPubMedCrossRefGoogle Scholar
  164. Mendlovic S, Fricke H, Shoenefeld Y, Mozes E (1989) The role of anti-idiotypic antibodies in the induction of experimental systemic lupus erythematosus in mice. Eur J Immunol 19:729. doi: 10.1002/eji.1830190424 PubMedCrossRefGoogle Scholar
  165. Miller DH, Khan QA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O’Connor PW, International Natalizumab Multiple Sclerosis Trial Group (2003a) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 53:466–472Google Scholar
  166. Miller RK, Mace K, Polliotti B, DeRita R, Hall W, Treacy G (2003b) Marginal transfer of ReoPro (Abciximab) compared with immunoglobulin G (F105), inulin and water in the perfused human placenta in vitro. Placenta 24:727–738. doi: 10.1016/S0143-4004(03)00101-2 PubMedCrossRefGoogle Scholar
  167. Miura Y, Fukuhara N, Yamamoto J, Kohata K, Ishizawa K, Ichinohasama R, Harigae H (2011) Clinicopathological features of malignant lymphoma in Japan: the Miyagi Study. Tohoku J Exp Med 224:151–160. doi: 10.1620/tjem.224.151 PubMedCrossRefGoogle Scholar
  168. Mkrtichyan M, Najjar YG, Raulfs EC, Abdalla MY, Samara R, Rotem-Yehudar R, Cook L, Khleif SN (2011) Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Eur J Immunol 41(10):2977–2986. doi: 10.1002/eji.201141639 PubMedCrossRefGoogle Scholar
  169. Mobbs KJ, Smyth RL, O’Hea U, Ashby D, Ritson P, Hart CA (2002) Cytokines in severe respiratory syncytial virus bronchiolitis. Pediatr Pulmonol 33:449–452. doi: 10.1002/ppul.10101 PubMedCrossRefGoogle Scholar
  170. Modi M, Singla M, Aggarwal N, Singla V, Sharma A (2010) Guillain-Barré syndrome in pregnancy: a rare complication of varicella. Taiwan J Obstet Gynecol 49:364–365. doi: 10.1016/S1028-4559(10)60076-9 PubMedCrossRefGoogle Scholar
  171. Molvarec A, Kalabay L, Derzsy Z, Szarka A, Halmos A, Stenczer B, Arnaud P, Karádi I, Prohászka Z, Rigó J Jr (2009a) Preeclampsia is associated with decreased serum alpha(2)-HS glycoprotein (fetuin-A) concentration. Hypertens Res 32:665–669PubMedCrossRefGoogle Scholar
  172. Molvarec A, Derzsy Z, Kocsis J, Boze T, Nagy B, Balogh K, Makó V, Cervenak L, Mézes M, Karádi I, Prohászka Z, Rigó J Jr (2009b) Circulating anti-heat-shock-protein antibodies in normal pregnancy and preeclampsia. Cell Stress Chaperones 14:491–498Google Scholar
  173. Morel E, Eymard B, Vernet Der-Garabedian B, Pannier C, Dulac O, Bach JF (1988) Neonatal myasthenia gravis-A new clinical and immunologic appraisal on 30 cases. Neurology 38:138PubMedGoogle Scholar
  174. Mori S (2011) Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. Mod Rheumatol 21(6):621–627PubMedCrossRefGoogle Scholar
  175. Morris BD, Nuss D, Winship WS (1977) Biliary atresia in a twin. S Afr Med J 51:469–470PubMedGoogle Scholar
  176. Morris LG, Hochster HS, Delacure MD (2011) Eyelash trichomegaly secondary to panitumumab therapy. Curr Oncol 18:145–146. doi: 10.3747/co.v18i3.762 PubMedCrossRefGoogle Scholar
  177. Mubashir E, Ahmed MM, Hayat S, Latif S, Heldmann M, Berney SM (2006) Wegener granulomatosis: a case report and update. South Med J 99:977–988. doi: 10.1097/01.smj.0000232210.04881.d3, ReviewPubMedCrossRefGoogle Scholar
  178. Muraji T, Hosaka N, Irie N, Yoshida M, Imai Y, Tanaka K, Takada Y, Sakamoto S, Haga H, Ikehara S (2008) Maternal microchimerism in underlying pathogenesis of biliary atresia: quantification and phenotypes of maternal cells in the liver. Pediatrics 121:517–521. doi: 10.1542/peds.2007-0568 PubMedCrossRefGoogle Scholar
  179. Murashima A, Watanabe N, Ozawa N, Saito H, Yamaguchi K (2009) Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant’s serum. Ann Rheum Dis 68:1793–1794. doi: 10.1136/ard.2008.105924 PubMedCrossRefGoogle Scholar
  180. Murray JL, Gillogly M, Kawano K, Efferson CL, Lee JE, Ross M, Wang X, Ferrone S, Ioannides CG (2004) Fine specificity of high molecular weight-melanoma-associated antigen-specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma. Cancer Res 64:5481–5488. doi: 10.1158/0008-5472.CAN-04-0517 PubMedCrossRefGoogle Scholar
  181. Naganuma M, Kunisaki R, Yoshimura N, Nagahori M, Yamamoto H, Kimura H, Sako M, Kawaguchi T, Takazoe M, Yamamoto S, Matsui T, Hibi T, Watanabe M (2011) Conception and pregnancy outcome in women with inflammatory bowel disease: A multicentre study from Japan. J Crohns Colitis 5:317–323. doi: 10.1016/j.crohns.2011.02.003 PubMedCrossRefGoogle Scholar
  182. Nageswara Rao AA, Rodriguez V, Long ME, Winters JL, Nichols WL, Pruthi RK (2009) Transient neonatal acquired von Willebrand syndrome due to transplacental transfer of maternal monoclonal antibodies. Pediatr Blood Cancer 53:655–657. doi: 10.1002/pbc.22084 PubMedCrossRefGoogle Scholar
  183. Nahmias AJ, Nahmias SB, Danielsson D (2006) The possible role of transplacentally-acquired antibodies to infectious agents, with molecular mimicry to nervous system sialic acid epitopes, as causes of neuromental disorders: prevention and vaccine implications. Clin Dev Immunol 13:167–183. doi: 10.1080/17402520600801745, ReviewPubMedCrossRefGoogle Scholar
  184. Nakajima K, Wakiguchi H, Kodama H, Sano S (2011) Neonatal lupus erythematosus in identical twins, showing transient bullous lesions. Pediatr Dermatol 28:397–400. doi: 10.1111/j.1525-1470.2010.01197.x PubMedCrossRefGoogle Scholar
  185. Namba T, Brown SB, Grob D (1970) Neonatal myasthenia gravis: report of two cases and review of literature. Pediatrics 45:488PubMedGoogle Scholar
  186. Naugler WE, Karin M (2008) The wolf in sheep’s clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 14:109–119. doi: 10.1016/j.molmed.2007.12.007 PubMedCrossRefGoogle Scholar
  187. Naugler WE, Sakurai T, Kim S, Kim KH, Maeda S, Elsharkawy AM, Karin M (2007) Gender disparity in liver cancer due to sex differences in MyD88- dependent IL-6 production. Science 317:121–124. doi: 10.1126/science.1140485 PubMedCrossRefGoogle Scholar
  188. Nelson JL (2002) Microchimerism: incidental byproduct of pregnancy or active participant in human health? Trends Mol Med 8:109–113. doi: 10.1016/S1471-4914(01)02269-9 PubMedCrossRefGoogle Scholar
  189. Nguyen DT, de Witte L, Ludlow M, Yüksel S, Wiesmüller KH, Geijtenbeek TB, Osterhaus AD, de Swart RL (2010) The synthetic bacterial lipopeptide Pam3CSK4 modulates respiratory syncytial virus infection independent of TLR activation. PLoS Pathog 6:e1001049. doi: 10.1371/journal.ppat.1001049 PubMedCrossRefGoogle Scholar
  190. Nieri P, Donadio E, Rossi S, Adinolfi B, Podestà A (2009) Antibodies for therapeutic uses and the evolution of biotechniques. Curr Med Chem 16:753–779. doi: 10.2174/092986709787458380, ReviewPubMedCrossRefGoogle Scholar
  191. Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK (2007) High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 8:492–502. doi: 10.1038/sj.gene.6364408 PubMedCrossRefGoogle Scholar
  192. Niklasson B, Hörnfeldt B, Lundman B (1998) Could myocarditis, insulin dependent diabetes mellitus, and Guillain-Barré syndrome be caused by one or more infections agents carried by rodents. Emerg Infect Dis 4:187–193. doi: 10.3201/eid0402.980206 PubMedCrossRefGoogle Scholar
  193. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T (2008) Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112:3959–3964. doi: 10.1182/blood-2008-05-155846 PubMedCrossRefGoogle Scholar
  194. O’Carroll P, Bertorini TE, Jacob G, Mitchell CW, Graff J (2009) Transient neonatal myasthenia gravis in a baby born to a mother with new-onset anti-MuSK-mediated myasthenia gravis. J Clin Neuromuscul Dis 11:69–71PubMedCrossRefGoogle Scholar
  195. Ochiai H, Kurokawa M, Kuroki Y, Niwayama S (1990) Infection enhancement of influenza A H1 subtype viruses in macrophage-like P388D1 cells by cross-reactive antibodies. J Med Virol 30:258–265. doi: 10.1002/jmv.1890300406 PubMedCrossRefGoogle Scholar
  196. Ohlsson A, Lacy J (2010) Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst Rev (3):CD001239, 17 Mar 2010Google Scholar
  197. Openshaw PJ, Culley FJ, Olszewska W (2001) Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine 20(Suppl 1):S27–S31. doi: 10.1016/S0264-410X(01)00301-2 PubMedCrossRefGoogle Scholar
  198. Ortiz-Santamaria V, Olive A, Martinez-Cáceres E, Coll M, Codina X, Surís X (2010) Neonatal lupus erythematosus: a possible role for anti-Sm antibodies. Lupus 19:659–661. doi: 10.1177/0961203309349385 PubMedCrossRefGoogle Scholar
  199. Osiowy C, Horne D, Anderson R (1994) Antibody-dependent enhancement of respiratory syncytial virus infection by sera from young infants. Clin Diagn Lab Immunol 1:670–677PubMedGoogle Scholar
  200. Oskoui M, Jacobson L, Chung WK, Haddad J, Vincent A, Kaufmann P, De Vivo DC (2008) Fetal acetylcholine receptor inactivation syndrome and maternal myasthenia gravis. Neurology 71:2010–2012. doi: 10.1212/01.wnl.0000336929.38733.7a PubMedCrossRefGoogle Scholar
  201. Østensen M, Förger F (2011) Treatment with biologics of pregnant patients with rheumatic diseases. Curr Opin Rheumatol 23:293–298. doi: 10.1097/BOR.0b013e328344a732 PubMedCrossRefGoogle Scholar
  202. Østensen M, Lockshin M, Doria A, Valesini G, Meroni P, Gordon C, Brucato A, Tincani A (2008) Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology (Oxford) 47(Suppl 3):iii28–iii31CrossRefGoogle Scholar
  203. Osterhaus AD, Rimmelzwaan GF, Weijer K, Uytdehaag AG (1989) Induction of anti-viral immune response by immunization with monoclonal anti-idiotype antibodies directed to private idiotopes. Viral Immunol 2:255–262. doi: 10.1089/vim.1989.2.255 PubMedCrossRefGoogle Scholar
  204. Ottosson L, Salomonsson S, Hennig J, Sonesson SE, Dörner T, Raats J, Kuchroo VK, Sunnerhagen M, Wahren-Herlenius M (2005) Structurally derived mutations define congenital heart block-related epitopes within the 200-239 amino acid stretch of the Ro52 protein. Scand J Immunol 61:109–118PubMedCrossRefGoogle Scholar
  205. Ozkan H, Cetinkaya M, Köksal N, Ali R, Güneş AM, Baytan B, Ozkalemkaş F, Ozkocaman V, Ozçelik T, Günay U, Tunali A, Kimya Y, Cengiz C (2010) Neonatal outcomes of pregnancy complicated by idiopathic thrombocytopenic purpura. J Perinatol 30:38–44PubMedCrossRefGoogle Scholar
  206. Partlett R, Roussou E (2011) The treatment of rheumatoid arthritis during pregnancy. Rheumatol Int 31:445–449. doi: 10.1007/s00296-010-1643-7 PubMedCrossRefGoogle Scholar
  207. Peciña A, Lozano Arana MD, García-Lozano JC, Borrego S, Antiñolo G (2010) One-step multiplex polymerase chain reaction for preimplantation genetic diagnosis of Huntington disease. Fertil Steril 93:2411–2412. doi: 10.1016/j.fertnstert.2009.01.120 PubMedCrossRefGoogle Scholar
  208. Pentsuk N, van der Laan JW (2009) An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol 86:328–344. doi: 10.1002/bdrb.20201, ReviewPubMedCrossRefGoogle Scholar
  209. Perez MF, de Torres ME, Buján MM, Lanoë A, Cervini AB, Pierini AM (2011) Neonatal lupus erythematosus: a report of four cases. An Bras Dermatol 86:347. doi: 10.1590/S0365-05962011000200021 PubMedCrossRefGoogle Scholar
  210. Perl A (2010) Pathogenic mechanisms in systemic lupus erythematosus. Autoimmunity 43:1–6. doi: 10.3109/08916930903374741 PubMedCrossRefGoogle Scholar
  211. Perl A, Fernandez D, Telarico T, Phillips PE (2010) Endogenous retroviral pathogenesis in lupus. Curr Opin Rheumatol 22:483–492. doi: 10.1097/BOR.0b013e32833c6297, ReviewPubMedCrossRefGoogle Scholar
  212. Petrou P, Georgalas I, Giavaras G, Anastasiou E, Ntana Z, Petrou C (2009) Early loss of pregnancy after intravitreal bevacizumab injection. Acta Ophthalmol 88:e136. doi: 10.1111/j.1755-3768.2009.01572.x PubMedCrossRefGoogle Scholar
  213. Pham T, Claudepierre P, Constantin A, de Bandt M, Fautrel B, Gossec L, Gottenberg JE, Goupille P, Guillaume S, Hachulla E, Masson C, Morel J, Puéchal X, Saraux A, Schaeverbeke T, Wendling D, Bruckert E, Pol S, Mariette X, Sibilia J, Club Rhumatismes et Inflammation (CRI) (2010) Tocilizumab: therapy and safety management. Joint Bone Spine 77(Suppl 1):S3–S100. doi: 10.1016/S1297-319X(10)70001-4 PubMedCrossRefGoogle Scholar
  214. Piehl F, Holmén C, Hillert J, Olsson T (2011) Swedish natalizumab (Tysabri) multiple sclerosis surveillance study. Neurol Sci 31:289. doi: 10.1007/s10072-010-0345-y PubMedCrossRefGoogle Scholar
  215. Powell DJ Jr, Attia P, Ghetie V, Schindler J, Vitetta ES, Rosenberg SA (2008) Partial reduction of human FOXP31 CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration. J Immunother 31:189–198. doi: 10.1097/CJI.0b013e31815dc0e8 PubMedCrossRefGoogle Scholar
  216. Pride MW, Shuey S, Grillo-Lopez A, Braslawsky G, Ross M, Legha SS, Eton O, Buzaid A, Ioannides C, Murray JL (1998) Enhancement of cell-mediated immunity in melanoma patients immunized with murine anti-idiotypic monoclonal antibodies (MELIMMUNE) that mimic the high molecular weight proteoglycan antigen. Clin Cancer Res 4:2363–2370PubMedGoogle Scholar
  217. Psaila B, Bussel JB (2008) Fc receptors in immune thrombocytopenias: a target for immunomodulation? J Clin Invest 118:2677–2681. doi: 10.1172/JCI36451 PubMedGoogle Scholar
  218. Psaila B, Bussel JB, Frelinger AL, Babula B, Linden MD, Li Y, Barnard MR, Tate C, Feldman EJ, Michelson AD (2011) Differences in platelet function in patients with acute myeloid leukaemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia. J Thromb Haemost 9(11):2302–2310. doi: 10.1111/j.1538-7836.2011.04506.x PubMedCrossRefGoogle Scholar
  219. Quatrale AE, Petriella D, Porcelli L, Tommasi S, Silvestris N, Colucci G, Angelo A, Azzariti A (2011) Nti-EGFR monoclonal antibody in cancer treatment: in vitro and in vivo evidence. Front Biosci 16:1973–1985. doi:10.2741/3834ű, ReviewPubMedCrossRefGoogle Scholar
  220. Quer J, Buti M, Cubero M, Guardia J, Esteban R., Esteban JI (2010) New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents. Infect Drug Resist 3:133–145. doi: 10.2147/IDR.S7136 Google Scholar
  221. Rabascio C, Laszlo D, Andreola G, Saronni L, Radice D, Rigacci L, Fabbri A, Frigeri F, Calabrese L, Billio A, Bertolini F, Martinelli G (2010) Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström’s Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2′-deoxyadenosine (2-CdA) and Rituximab. Leuk Res 34:454–457PubMedCrossRefGoogle Scholar
  222. Radetti G, Zavallone A, Gentili L, Beck-Peccoz P, Bona G (2002) Foetal and neonatal thyroid disorders. Minerva Pediatr 54:383–400PubMedGoogle Scholar
  223. Rak JM, Maestroni L, Balandraud N, Guis S, Boudinet H, Guzian MC, Yan Z, Azzouz D, Auger I, Roudier C, Martin M, Didelot R, Roudier J, Lambert NC (2009) Transfer of the shared epitope through microchimerism in women with rheumatoid arthritis. Arthritis Rheum 60:73–80. doi: 10.1002/art.24224 PubMedCrossRefGoogle Scholar
  224. Rech AJ, Vonderheide RH (2009) Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 1174:99–106. doi: 10.1111/j.1749-6632.2009.04939.x PubMedCrossRefGoogle Scholar
  225. Reece DE, Foon KA, Bhattacharya-Chatterjee M, Hale GA, Howard DS, Munn RK, Nath R, Plummer BA, Teitelbaum A, Phillips GL (2000) Use of the anti-idiotype antibody vaccine TriAb after autologous stem cell transplantation in patients with metastatic breast cancer. Bone Marrow Transpl 26:729–735. doi: 10.3816/CBC.2001.n.011 CrossRefGoogle Scholar
  226. Reece DE, Foon KA, Battacharya-Chatterjee M, Adkins D, Broun ER, Connaghan DG, Dipersio JF, Holland HK, Howard DS, Hale GA, Klingemann HG, Munn RK, Raptis A, Phillips GL (2001) Interim analysis of the use of the anti-idiotype breast cancer vaccine 11D10 (TriAb) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer. Clin Breast Cancer 2:52–58. doi: 10.3816/CBC.2001.n.011 PubMedCrossRefGoogle Scholar
  227. Reece DE, Foon KA, Bhattarcharya-Chatterjee M, Adkins D, Broun ER, Connaghan DG, Dipersio JF, Holland HK, Howard DA, Hale GA, Klingemann HG, Munn RK, Raptis A, Phillips GL (2003) Use of the anti-idiotype breast cancer vaccine 11D10 in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer. Clin Breast Cancer 3(Suppl 4):S152–S157. doi: 10.3816/CBC.2003.s.005 PubMedCrossRefGoogle Scholar
  228. Reinartz S, Hombach A, Köhler S, Schlebusch H, Wallwiener D, Abken H, Wagner U (2003) Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer. Cancer Res 63:3234–3240PubMedGoogle Scholar
  229. Reinisch W, de Villiers W, Bene L, Simon L, Rácz I, Katz S, Altorjay I, Feagan B, Riff D, Bernstein CN, Hommes D, Rutgeerts P, Cortot A, Gaspari M, Cheng M, Pearce T, Sands BE (2010) Fontolizumab in moderate to severe Crohn’s disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis 16:233–242PubMedGoogle Scholar
  230. Robinson AA, Watson WJ, Leslie K (2007) Targeted treatment using monoclonal antibodies and tyrosine-kinase inhibitors in pregnancy. Lancet Oncol 8:738–743PubMedCrossRefGoogle Scholar
  231. Routsias JG, Kyriakidis NC, Friedman DM, Llanos C, Clancy R, Moutsopoulos HM, Buyon J, Tzioufas AG (2011) Association of the idiotype:anti-idiotype antibody ratio with the efficacy of intravenous immunoglobulin treatment for the prevention of recurrent autoimmune-associated congenital heart block. Arthritis Rheum 63:2783–2789. doi: 10.1002/art.30464 PubMedCrossRefGoogle Scholar
  232. Rubio-Cabezas O, Klupa T, Malecki MT, CEED3 Consortium (2011) Permanent neonatal diabetes mellitus – the importance of diabetes differential diagnosis in neonates and infants. Eur J Clin Invest 41(3):323–333. doi: 10.1111/j.1365-2362.2010.02409.x PubMedCrossRefGoogle Scholar
  233. Ruiz-Irastorza G, Khamashta MA (2011) Lupus and pregnancy: integrating clues from the bench and bedside. Eur J Clin Invest 41:672–678. doi: 10.1111/j.1365-2362.2010.02443.x PubMedCrossRefGoogle Scholar
  234. Rüssel J, Stein A, Behrmann C, Hauptmann S, Krummenerl P, Schmoll HJ, Arnold D (2011) Inflammatory lesions of the peritoneum mimic carcinomatosis after treatment with intravenous chemotherapy and intraperitoneal catumaxomab. J Clin Oncol 29:e644–e646PubMedCrossRefGoogle Scholar
  235. Russo L, Iafusco D, Brescianini S, Nocerino V, Bizzarri C, Toni S, Cerutti F, Monciotti C, Pesavento R, Iughetti L, Bernardini L, Bonfanti R, Gargantini L, Vanelli M, Aguilar-Bryan L, Stazi MA, Grasso V, Colombo C, Barbetti F, ISPED Early Diabetes Study Group (2011) Permanent diabetes during the first year of life: multiple gene screening in 54 patients. Diabetologia 54:1693–1701. doi: 10.1007/s00125-011-2094-8 PubMedCrossRefGoogle Scholar
  236. Rutgeerts P, Ververmeire S, Van Assche G (2009) Biological therapies for inflammatory bowel diseases. Gastroenterology 136:1182–1197. doi: 10.1053/j.gastro.2009.02.001 PubMedCrossRefGoogle Scholar
  237. Sadler TW (2004) Langman’s medical embryology, 9th edn. Lippincott Williams and Wilkins, PhiladelphiaGoogle Scholar
  238. Saito Y, Nakahata S, Yamakawa N, Kaneda K, Ichihara E, Suekane A, Morishita K (2011) CD52 as a molecular target for immunotherapy to treat acute myeloid leukemia with high EVI1 expression. Leukemia 25:921–931. doi: 10.1038/leu.2011.36 PubMedCrossRefGoogle Scholar
  239. Sakaguchi S (2004) Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531–562. doi: 10.1146/annurev.immunol.21.120601.141122 PubMedCrossRefGoogle Scholar
  240. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self tolerance causes various autoimmune diseases. J Immunol 15:1151–1164Google Scholar
  241. Saleem B, Mackie S, Quinn M, Nizam S, Hensor E, Jarrett S, Conaghan PG, Emery P (2008) Does the use of tumour necrosis factor antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis? Ann Rheum Dis 67:1178–1180. doi: 10.1136/ard.2007.084269 PubMedCrossRefGoogle Scholar
  242. Salek-Ardakani S, Arens R, Flynn R, Sette A, Schoenberger SP, Croft M (2009) Preferential use of B7.2 and not B7.1 in priming of vaccinia virus-specific CD8 T cells. J Immunol 182:2909–2918. doi: 10.4049/jimmunol.0803545 PubMedCrossRefGoogle Scholar
  243. Salvetti M, Giovannoni G, Aloisi F (2009) Epstein-Barr virus and multiple sclerosis. Curr Opin Neurol 22:201–206. doi: 10.1097/WCO.0b013e32832b4c8d, ReviewPubMedCrossRefGoogle Scholar
  244. Sandberg-Wollheim M, Alteri E, Moraga MS, Kornmann G (2011) Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler 17:423–430. doi: 10.1177/1352458510394610 PubMedCrossRefGoogle Scholar
  245. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P (2005) Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med 353:1912–1925. doi: 10.1056/NEJMoa043335 PubMedCrossRefGoogle Scholar
  246. Sansom DM, Walker LS (2006) The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol Rev 212:131–148. doi: 10.1111/j.0105-2896.2006.00419.x PubMedCrossRefGoogle Scholar
  247. Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, Bendig MM (1993) Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 53:851–856PubMedGoogle Scholar
  248. Schmitz H, Essuman S (1986) Comparison of the neutralizing and ELISA antibody titres to human cytomegalovirus (HCMV) in human sera and in gamma globulin preparations. J Med Virol 20:177–182. doi: 10.1002/jmv.1890200209 PubMedCrossRefGoogle Scholar
  249. Schnitzler F, Fidder H, Ferrante M, Ballet V, Noman M, Van Assche G, Spitz B, Hoffman I, Van Steen K, Vermeire S, Rutgeerts P (2011) Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 17:1846. doi: 10.1002/ibd.21583 PubMedCrossRefGoogle Scholar
  250. Seiden MV, Burris HA, Matulonis U, Hall JB, Armstrong DK, Speyer J, Weber JD, Muggia F (2007) A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol 104:727–731. doi: 10.1016/j.ygyno.2006.10.019 PubMedCrossRefGoogle Scholar
  251. Sherer Y, Blank M, Shoenfeld Y (2007) Antiphospholipid syndrome (APS): where does it come from? Best Pract Res Clin Rheumatol 21:1071–1078. doi: 10.1016/j.berh.2007.09.005 PubMedCrossRefGoogle Scholar
  252. Simone JV, Cornet JA, Abildgaard CF (1968) Acquired von Willebrand’s syndrome in systemic lupus erythematosus. Blood 31:806–812PubMedGoogle Scholar
  253. Sladky JT (2004) Guillain-Barré syndrome in children. J Child Neurol 19:191–200Google Scholar
  254. Smith SH, Haas KM, Poe JC, Yanaba K, Ward CD, Migone TS, Tedder TF (2010) B-cell homeostasis requires complementary CD22 and BLyS/BR3 survival signals. Int Immunol 22:681–691. doi: 10.1093/intimm/dxq055 PubMedCrossRefGoogle Scholar
  255. Sodani P, Isgrò A, Gaziev J, Polchi P, Paciaroni K, Marziali M, Simone MD, Roveda A, Montuoro A, Alfieri C, De Angelis G, Gallucci C, Erer B, Isacchi G, Zinno F, Adorno G, Lanti A, Faulkner L, Testi M, Andreani M, Lucarelli G (2010) Purified T-depleted, CD34+ peripheral blood and bone marrow cell transplantation from haploidentical mother to child with thalassemia. Blood 115(6):1296–1302Google Scholar
  256. Somerset DA, Zheng Y, Kilby MD, Samson DM, Drayson MT (2004) Normal human pregnancy is associated with an elevation in the immune suppressive CD4+CD25+ regulatory T-cell subset. Immunology 112:38–43. doi: 10.1111/j.1365-2567.2004.01869.x PubMedCrossRefGoogle Scholar
  257. Spicer J (2005) Technology evaluation: nimotuzumab, the Center of Molecular Immunology/YM BioSciences/Oncoscience. Curr Opin Mol Ther 7:182–191, ReviewPubMedGoogle Scholar
  258. Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, Teng MW, Smyth MJ (2011) Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci USA 108:7142–7147. doi: 10.1073/pnas.1016569108 PubMedCrossRefGoogle Scholar
  259. Staii A, Mirocha S, Todorova-Koteva K, Glinberg S, Jaume JC (2010) Hashimoto thyroiditis is more frequent than expected when diagnosed by cytology which uncovers a pre-clinical state. Thyroid Res 3:11. doi: 10.1186/1756-6614-3-11 PubMedCrossRefGoogle Scholar
  260. Stone MS, Olson RR, Weismann DN, Giller RH, Goeken JA (1993) Cutaneous vasculitis in the newborn of a mother with cutaneous polyarteritis nodosa. J Am Acad Dermatol 28:101–105. doi: 10.1016/0190-9622(93)70020-T PubMedCrossRefGoogle Scholar
  261. Sukumvanich P (2011) Review of current treatment options for pregnancy-associated breast cancer. Clin Obstet Gynecol 54:164–172. doi: 10.1097/GRF.0b013e3182083a44, ReviewPubMedCrossRefGoogle Scholar
  262. Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M, Yamada T, Hanaoka N, Inui K, Wada H (2001) Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 7:3410–3415PubMedGoogle Scholar
  263. Tarantola RM, Folk JC, Boldt HC, Mahajan VB (2010) Intravitreal bevacizumab during pregnancy. Retina 30:1405–1411. doi: 10.1097/IAE.0b013e3181f57d58 PubMedCrossRefGoogle Scholar
  264. Thapa R, Pramanik S, Dhar S, Kundu R (2007) Neonatal Kawasaki disease with multiple coronary aneurysms and thrombocytopenia. Pediatr Dermatol 24:662–663. doi: 10.1111/j.1525-1470.2007.00563.x PubMedCrossRefGoogle Scholar
  265. The Huntington’s Disease Collaborative Research Group (HDCRG) (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72:971–983CrossRefGoogle Scholar
  266. Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, Nye SH, Matis LA, Squinto SP, Evans MJ (1996) Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 33:1389–1401. doi: 10.1016/S0161-5890(96)00078-8 PubMedCrossRefGoogle Scholar
  267. Tincani A, Rebaioli CB, Andreoli L, Lojacono A, Motta M (2009) Neonatal effects of maternal antiphospholipid syndrome. Curr Rheumatol Rep 11:70–76. doi: 10.1007/s11926-009-0010-8, ReviewPubMedCrossRefGoogle Scholar
  268. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Scarpe AH (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541–547. doi: 10.1016/1074-7613(95)90125-6 PubMedCrossRefGoogle Scholar
  269. Tonra JR, Deevi DS, Corcoran E, Li H, Moeljadi P, Huber J, Ludwig D, Surguladze D, Hicklin D (2006) Combined antibody mediated inhibition of IGF-1R, EGFR, VEGFR2 for more consistent and greater anti-tumor effects. Eur J Cancer 4:207. doi: 10.1016/S1359-6349(06)70212-9 Google Scholar
  270. Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, Horst HA, Raff T, Viardot A, Schmid M, Stelljes M, Schaich M, Degenhard E, Köhne-Volland R, Brüggemann M, Ottmann O, Pfeifer H, Burmeister T, Nagorsen D, Schmidt M, Lutterbuese R, Reinhardt C, Baeuerle PA, Kneba M, Einsele H, Riethmüller G, Hoelzer D, Zugmaier G, Bargou RC (2011) Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 29:2493–2498. doi: 10.1200/JCO.2010.32.7270 PubMedCrossRefGoogle Scholar
  271. Tregoning JS, Yamaguchi Y, Harker J, Wang B, Openshaw PJ (2008) The role of T cells in the enhancement of respiratory syncytial virus infection severity during adult reinfection of neonatally sensitized mice. J Virol 82:4115–4124PubMedCrossRefGoogle Scholar
  272. Turowski C, Leonhardt J, Teichmann B, Heim A, Baumann U, Kuebler JF, Petersen C (2010) Preconceptional oral vaccination prevents experimental biliary atresia in newborn mice. Eur J Pediatr Surg 20:158–163. doi: 10.1055/s-0030-1249700 PubMedCrossRefGoogle Scholar
  273. Tzartos SJ, Efthimiadis A, Morel E, Eymardt B, Bach J-F (1990) Neonatal myasthenia gravis: antigenic specificities of antibodies in sera from mothers and their infants. Clin Exp Immunol 80:376–380. doi: 10.1111/j.1365-2249.1990.tb03296.x PubMedCrossRefGoogle Scholar
  274. Tzioufas AG, Routsias JG (2010) Idiotype, anti-idiotype network of autoantibodies: pathogenetic considerations and clinical application. Autoimmun Rev 9:631–633. doi: 10.1016/j.autrev.2010.05.013 PubMedCrossRefGoogle Scholar
  275. Ubol S, Halstead SB (2010) How innate immune mechanisms contribute to antibody-enhanced viral infections. Clin Vaccine Immunol 17:1829–1835. doi: 10.1128/CVI.00316-10, ReviewPubMedCrossRefGoogle Scholar
  276. Umeda N, Ito S, Hayashi T, Goto D, Matsumoto I, Sumida T (2010) A patient with rheumatoid arthritis who had a normal delivery under etanercept treatment. Intern Med 49:187–189. doi: 10.2169/internalmedicine.49.2439 PubMedCrossRefGoogle Scholar
  277. Urbain R, Teillaud JL, Prost JF (2009) EMABling antibodies: from feto-maternal allo-immunisation prophylaxis to chronic lymphocytic leukaemia therapy. Med Sci (Paris) 25:1141–1144. doi: 10.1051/medsci/200925121141, Review. FrenchCrossRefGoogle Scholar
  278. Vaidyanathan A, McKeever K, Anand B, Eppler S, Weinbauer G, Beyer J (2010) Developmental immunotoxicology assessment of rituximab in cynomolgus monkeys. Toxicol Sci 119(1):116–125. doi: 10.1093/toxsci/kfq316 PubMedCrossRefGoogle Scholar
  279. Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, Verbeeck J, Geboes K, Robberecht W, Rutgeerts P (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 353:362–368. doi: 10.1056/NEJMoa051586 PubMedCrossRefGoogle Scholar
  280. Van der Aa EM, Copius Peereboom-Stegeman JHJ, Noordhoek J, Gribnau FWJ, Russel FGM (1998) Mechanisms of drug transfer across the human placenta. Pharm World Sci 20:139–148. doi: 10.1023/A:1008656928861 PubMedCrossRefGoogle Scholar
  281. van Dongen H, van Aken J, Lard LR, Visser K, Ronday HK, Hulsmans HMJ, Speyer I, Westedt M-L, Peeters AJ, Allaart CF, Toes REM, Breedveld FC, Huizinga TWJ (2007) Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 56:1424–1432. doi: 10.1002/art.22525 PubMedCrossRefGoogle Scholar
  282. van Schouwenburg PA, Bartelds GM, Hart MH, Aarden L, Wolbink GJ, Wouters D (2010) A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients. J Immunol Methods 362:82–88. doi: 10.1016/j.jim.2010.09.005 PubMedCrossRefGoogle Scholar
  283. Varghese S, Crocker I, Bruce IN, Tower C (2011) Systemic lupus erythematosus, regulatory T cells and pregnancy. Expert Rev Clin Immunol 7:635–648. doi: 10.1586/eci.11.59 PubMedCrossRefGoogle Scholar
  284. Veerappan SG, O’Morain CA, Daly JS, Ryan BM (2011) Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease. Aliment Pharmacol Ther 33(12):1261–1272. doi: 10.1111/j.1365-2036.2011.04667.x PubMedCrossRefGoogle Scholar
  285. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA (2004) Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. Exp Med 199:971–979. doi: 10.1084/jem.20031579 CrossRefGoogle Scholar
  286. Villiger PM, Caliezi G, Cottin V, Förger F, Senn A, Østensen M (2010) Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis. Ann Rheum Dis 69:1842–1844. doi: 10.1136/ard.2009.127423 PubMedCrossRefGoogle Scholar
  287. Vinet E, Pineau C, Gordon C, Clarke AE, Bernatsky S (2009) Biologic therapy and pregnancy outcomes in women with rheumatic diseases. Arthritis Rheum 61:587–592. doi: 10.1002/art.24462 PubMedCrossRefGoogle Scholar
  288. Voisard R, Alan M, von Müller L, Baur R, Hombach V (2006) Effects of abciximab on key pattern of human coronary restenosis in vitro: impact of the SI/MPL-ratio. BMC Cardiovasc Disord 6:14–19PubMedCrossRefGoogle Scholar
  289. Voorhees PM, Chen Q, Small GW, Kuhn DJ, Hunsucker SA, Nemeth JA, Orlowski RZ (2009) Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol 145:481–490. doi: 10.1111/j.1365-2141.2009.07647.x PubMedCrossRefGoogle Scholar
  290. Wafula PO, Teles A, Schumacher A, Pohl K, Yagita H, Volk HD, Zenclussen AC (2009) PD-1 but not CTLA-4 blockage abrogates the protective effect of regulatory T cells in a pregnancy murine model. Am J Reprod Immunol 62:283–292. doi: 10.1111/j.1600-0897.2009.00737.x PubMedCrossRefGoogle Scholar
  291. Wagner U, Schlebusch H, Köhler S, Schmolling J, Grünn U, Krebs D (1997) Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125. Hybridoma 16:33–40. doi: 10.1089/hyb.1997.16.33 PubMedCrossRefGoogle Scholar
  292. Wahren-Herlenius M (2010) Immunological contribution to the pathogenesis of congenital heart block. Scand J Immunol 72:171–172. doi: 10.1111/j.1365-3083.2010.02446.x PubMedCrossRefGoogle Scholar
  293. Wang G, Qiu J, Wang R, Krause A, Boyer JL, Hackett NR, Crystal RG (2010a) Persistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transfer. Cancer Gene Ther 17:559–570. doi: 10.1038/cgt.2010.11 PubMedCrossRefGoogle Scholar
  294. Wang SM, Chen IC, Su LY, Huang KJ, Lei HY, Liu CC (2010b) Enterovirus 71 infection of monocytes with antibody-dependent enhancement. Clin Vaccine Immunol 17:1517–1523. doi: 10.1128/CVI.00108-10 PubMedCrossRefGoogle Scholar
  295. Ward E, Mittereder N, Kuta E, Sims GP, Bowen MA, Dall’aqua W, Tedder T, Kiener P, Coyle AJ, Wu H, Jallal B, Herbst R (2011) A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. Br J Haematol 155(4):426–437. doi: 10.1111/j.1365-2141.2011.08857.x PubMedCrossRefGoogle Scholar
  296. Watanabe T (2011) Treatment strategies for nodal and gastrointestinal follicular lymphoma: current status and future development. World J Gastroenterol 16:5543–5554. doi: 10.3748 CrossRefGoogle Scholar
  297. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW (1995) Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270:985–988. doi: 10.1126/science.270.5238.985 PubMedCrossRefGoogle Scholar
  298. Watson WJ (2005) Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios. Obstet Gynecol 105:642–643. doi: 10.1097/01.AOG.0000141570.31218.2b PubMedCrossRefGoogle Scholar
  299. Watson RM, Lane AT, Barnett NK, Bias WB, Arnett FC, Provost TT (1984) Neonatal lupus erythematosus. A clinical, serological and immunogenetic study with review of the literature. Medicine 63:362–378. doi: 10.1097/00005792-198411000-00003 PubMedCrossRefGoogle Scholar
  300. Wehner NG, Shopp G, Osterburg I, Fuchs A, Buse E, Clarke J (2009a) Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol 86:144–156. doi: 10.1002/bdrb.20193 PubMedCrossRefGoogle Scholar
  301. Wehner NG, Shopp G, Oneda S, Clarke J (2009b) Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol 86:117–130. doi: 10.1002/bdrb.20190 PubMedCrossRefGoogle Scholar
  302. Weisman LE (2009) Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations. Curr Opin Mol Ther 11:208–218PubMedGoogle Scholar
  303. Winger EE, Reed JL (2008) Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion. Am J Reprod Immunol 60:8–16. doi: 10.1111/j.1600-0897.2008.00585.x PubMedCrossRefGoogle Scholar
  304. Winter WE, Schatz D (2003) Prevention strategies for type 1 diabetes mellitus: current status and future directions. BioDrugs 17:39–64. doi: 10.2165/00063030-200317010-00004, ReviewPubMedCrossRefGoogle Scholar
  305. Xu L, Jain RK (2007) Down-regulation of placenta growth factor by promoter hypermethylation in human lung and colon carcinoma. Mol Cancer Res 5:873–880. doi: 10.1158/1541-7786.MCR-06-0141 PubMedCrossRefGoogle Scholar
  306. Ye M, Kasey S, Khurana S, Nguyen NT, Schubert S, Nugent CT, Kuus-Reichel K, Hampl J (2004) MHC class II tetramers containing influenza hemagglutinin and EBV EBNA1 epitopes detect reliably specific CD4+ T cells in healthy volunteers. Hum Immunol 65:507–513. doi: 10.1016/j.humimm.2004.02.019 PubMedCrossRefGoogle Scholar
  307. Zelinkova Z, de Haar C, de Ridder L, Pierik MJ, Kuipers EJ, Peppelenbosch MP, van der Woude CJ (2011) High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 33:1053–1058. doi: 10.1111/j.1365-2036.2011.04617.x PubMedCrossRefGoogle Scholar
  308. Zhang G, Basti S, Jampol L (2007) Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors. Cornea 26:858–860. doi: 10.1097/ICO.0b013e318064584a PubMedCrossRefGoogle Scholar
  309. Zhao R, Li H, Shen C, Zheng S (2011) RRAS: a key regulator and an important prognostic biomarker in biliary atresia. World J Gastroenterol 17:796–803. doi: 10.3748/wjg.v17.i6.796 PubMedCrossRefGoogle Scholar
  310. Zhu Z, Bossart KN, Bishop KA, Crameri G, Dimitrov AS, McEachern JA, Feng Y, Middleton D, Wang LF, Broder CC, Dimitrov DS (2008) Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. J Infect Dis 197:846–853. doi: 10.1517/14712590902763755 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  1. 1.Division of VirologyNational Center for EpidemiologyBudapestHungary

Personalised recommendations